Simon TG, Duberg AS, Aleman S, et al. - Via analyzing data from a prospective propensity score-matched cohort of 16,668 adults, researchers determined the association between lipophilic or hydrophilic statin use and hepatocellular carcinoma (HCC) incidence and mortality in a nationwide population with viral hepatitis. Ten-year HCC risk was significantly lower among lipophilic statin users—but not hydrophilic statin users—compared with matched nonusers. The inverse relationship between lipophilic statins and HCC risk appeared to be dose-dependent. Compared with nonusers, 10-year HCC risk was lowest with ≥ 600 lipophilic statin cumulative defined daily doses, and 10-year mortality was significantly lower among both lipophilic and hydrophilic statin users. Overall, lipophilic statins were related to significantly reduced HCC incidence and mortality. A relationship between hydrophilic statins and decreased risk for HCC was not observed.